Grail LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data evaluating the use and potential of its methylation-based multi-cancer early detection (MCED) platform at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6. Presentations include interim results from SYMPLIFY, the first large-scale prospective study to evaluate Grail’s MCED test in symptomatic patients referred for cancer suspicion, as well as Galleri real-world clinical surveillance data and subset analyses from the PATHFINDER clinical implementation study. An evaluation of Galleri implementation using a centralized model within Mercy’s multi-state health system will also be presented.
Related: Henry Ford Health Offers Multi-Cancer Early Detection Blood Test
“If we hope to bend the cancer mortality curve, we need a new, population-scale approach for screening people that finds many more cancers than we do today, in earlier stages when treatments are often more effective,” says Josh Ofman, MD, MSHS, president at Grail. “We believe that adding multi-cancer early detection testing to recommended screening is the best chance to address the growing burden of late-stage cancer in an aging population. We are excited to present new data at this year’s ASCO Annual Meeting supporting the use of Grail’s MCED technology in adults at elevated risk of cancer, as well as initial findings from SYMPLIFY, a study evaluating patients presenting with signs and symptoms who are referred for a cancer evaluation.”
Initial results from SYMPLIFY will be presented during an oral session. SYMPLIFY is the first prospective study assessing the clinical performance of Grail’s MCED Methylation Platform in individuals with signs and symptoms that may indicate cancer. Researchers will also present an analysis of the early real-world clinical experience using the Galleri MCED test to detect a shared cancer signal and predict cancer signal of origin (CSO) to guide targeted diagnostic workup.
Additionally, doctors from Mercy will present a preliminary analysis of an MCED test implementation model within a large health system utilizing a patient navigation system. A follow-up analysis to the PATHFINDER study assessing clinical implementation of the test following a cancer signal detected result and CSO-guided workups will also be presented. Results from the PATHFINDER study were previously reported during the European Society for Medical Oncology (ESMO) Congress 2022.
Abstracts will be available on the 2023 ASCO Annual Meeting website. Updated analyses will be presented at the Annual Meeting.